Polyhydroxyalkanoates (PHAs) are natural polymers produced by various microorganisms. Due to their biocompatibility and biodegradability, PHAs have numerous biomedical applications [1]: drug delivery systems, bone and cartilage regeneration, vascular system devices and wound management. It is also well known that exogenous ketone supplements are frequently used by those intending to lose weight and to increase exercise performance. [2]. There are various congeners of PHAs, but short chain length polymers such as poly-3-hydroxybutyrate (P3HB), poly-3-hydroxyvalerate (P3HV), poly-4-hydroxybutyrate (P4HB), poly-4-(hydroxyvalerate) and their copolymers are largely used in therapeutic applications [3]. Due to the autocatalytic degradation of these polymers, small oligomers are released in the human body. Within this study, we have used a computational approach to assess the pharmacokinetic profiles of small oligomers of 3-hydroxybutyrate, 3-hydroxyvalerate, 4-hydroxybutyrate, 4- hydroxyvalerate, and their co-oligomers. The outputs of our study suggest that investigated small oligomers have favorable pharmacokinetic profiles revealing good bioavailability, are not potential inhibitors of human cytochromes involved in drug metabolism, are not carcinogen and mutagen. The investigated oligomers are possible inhibitors of organ anion transporters OATP1B1 and OATP1B3, which may influence the absorption of some drugs in the liver and smaller molecular weight oligomers can cause eye irritation. [ABSTRACT FROM AUTHOR]